Eli Lilly NYSE:LLY secured another regulatory boost for olomorasib after the FDA granted breakthrough therapy designation to the experimental drug as a standalone treatment for previously treated, advanced pancreatic cancer carrying the KRAS G12C mutation. The decision could accelerate development…
The second-quarter 2026 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.With many pharma and biotech bigwigs having already reported results, the earnings picture has been encouraging. Nearly all of these comp…
Scribe Therapeutics (SCTX), a gene-editing company backed by Eli Lilly NYSE:LLY, raised $128.7 million after pricing an upsized initial public offering at the top of its expected range.The biotech sold 8.58 million shares at $15 each, with all of the stock coming directly from the company. Its shar…
Eli Lilly NYSE:LLY fell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The drug targets three metabolic hormones, GLP-1, GIP and glucagon, again…
Eli Lilly (LLY, Financials), a pharmaceutical firm that focuses on diabetes, obesity and other chronic diseases, said it aims to petition for regulatory approval of retatrutide in the first quarter of 2027 after the medicine succeeded in two more phase 3 trials.The filing comes later than previousl…
The AI and memory-chip rallies may have already minted their biggest winners, but biotech is mounting a breakout of its own, with the XBI biotech ETF sharply outperforming the broader market as cash-rich drugmakers race to buy promising pipelines before blockbuster patent losses begin eroding reven…
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.Th…
Plainsboro, NJ and Bagsværd, Denmark, 21 July 2026 – Novo Nordisk Inc. announced today that it has filed a lawsuit against Eli Lilly and Company and Lilly USA, LLC in the United States District Court for the District of New Jersey for multiple violations of federal and state false advertising and u…
Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial public offering. The Alameda, California-based biotechnology company plans to sell 7.2 million shares at between $13 and $15 each, according to a…
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley…
Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe…
Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in…
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depressionAcquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental healthINDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and C…
Eli Lilly (LLY) reportedly in advanced talks to buy AtaiBeckley for $9–$11/sh, a sizable premium; AtaiBeckley jumped in after-hours while Lilly stock showed little movement.Deutsch
Shares of AtaiBeckley Inc (ATAI) jumped 59% after-hours following reports that pharmaceutical giant Eli Lilly is close to a deal for the psychedelic drug developer.Eli Lilly (LLY) is nearing an agreement involving AtaiBeckley, Bloomberg reported on Wednesday, citing people familiar with the matter…
Eli Lilly (LLY, Financials), the pharmaceutical company behind several diabetes and weight-loss treatments, is off to a slower start than expected with its new obesity pill.U.S. prescription data for the week ended July 3 showed about 19,550 prescriptions for Lilly's Foundayo, compared with roughly…
Eli Lilly NYSE:LLY gained attention after Canada's Drug Agency issued a positive recommendation for its eczema treatment Ebglyss, a move that could broaden patient access through public drug plans.Eli Lilly said Ebglyss is recommended for people living with moderate-to-severe eczema after previousl…
WSW, NY, July 9th, 2026, FinanceWireIn June, Nuvectis Pharma NASDAQ:NVCT signed a deal that took it from a single-drug oncology company to the owner of one of the more closely watched assets in rare-disease medicine: NXP100, a once-a-day pill for a blood disorder called paroxysmal nocturnal hemoglo…
Eli Lilly (NYSE:LLY) secured Medicare coverage for Zepbound and Foundayo through a GLP‑1 Bridge program from July 1 to Dec 2027 with a $50 copay, boosting sales potential as FDA PreCheck for its Lebanon plant aids supply — though uptake, rollout, prior auth and short program duration pose risks.Pre…
